Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group ( (AU:MYX) ) has shared an announcement.
Mayne Pharma announced that its oral contraceptive, NEXTSTELLIS®, has been approved for reimbursement by the Australian Pharmaceutical Benefits Scheme (PBS), effective from October 1, 2025. This listing is expected to enhance access to contraceptive options in Australia, aligning with recommendations to improve access to newer hormonal contraceptives. NEXTSTELLIS® is notable for being the first contraceptive pill containing estetrol (E4), a natural estrogen, derived from a plant source. The PBS listing significantly reduces the cost for patients, making it more affordable and accessible, which is a positive development for women’s healthcare in Australia.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. It also provides contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has developed and commercialized numerous oral drug delivery systems worldwide.
YTD Price Performance: 3.82%
Average Trading Volume: 287,183
Technical Sentiment Signal: Sell
Current Market Cap: A$419.2M
See more data about MYX stock on TipRanks’ Stock Analysis page.